Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old
- People who have pancreatic cancer that has been classified as resectable, borderline resectable, or locally advanced, confirmed through CT scan, ultrasound, or other imaging
- People who are in reasonably good general health, as measured by a standard medical scoring system (ECOG score of 0–2) (confirm with trial site)
- People who have been fully informed about the study and have signed a written consent form approved by the relevant review board
- People whose cancer is suitable for a specialised type of radiation treatment (SBRT) at Johns Hopkins University
- People who are receiving initial treatment with a combination chemotherapy regimen
- People whose case is suitable for surgical exploration at Johns Hopkins University
Who may not be able to join:
- People who have previously had radiation therapy to the chest or abdomen
- People who are not able to receive SBRT treatment at Johns Hopkins University
- People whose cancer appears to have grown into the duodenum (part of the small intestine), as seen on imaging
- People whose tumour is located in the body or tail of the pancreas (rather than the head)
- People who are not able to undergo a Whipple procedure (a specific type of pancreatic surgery)
- People whose cancer appears to have spread beyond the pancreas
- People whose surgery would require reconstruction of any arteries
- People who are currently taking part in another clinical trial involving an experimental drug or device that would interfere with this study
- People who are unable to follow the study requirements or attend follow-up appointments
- Women who could become pregnant, or men with female partners who could become pregnant, who are unwilling or unable to use an accepted method of contraception for the full duration of the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amol Narang, MD, JHU, School of Medicine, SKCCC
Phone: 410-502-3828
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acute post-operative toxicity of targeted IORT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.